Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans

Bookmark and Share
Published: 19 Dec 2019
Views: 178
Rating:
Save
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland

Prof Adrian Ochsenbein speaks to ecancer at the 2019 ASH meeting in Orlando about a phase 1 study looking at the use of the anti-CD70 ADCC-optimised monoclonal antibody cusatuzumab in attacking acute myeloid leukaemia stem cells in humans.

He explains that the study was dose escalated with 12 patients and that a response rate of 100% was seen.

Prof Ochsenbein explains that the next steps are to await results from the expansion of an additional 26 patients which will hopefully hold more insights about potential biomarkers.